 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | CV Empat Bintang |
| Street 1: | Komplek Graha Kartika Pratama Blok DI 1 No. 35 |
| Street 2: | Cibinong |
| City: | Bogor |
| Province: | West Java |
| Post Code: | 16922 |
| Country: | Indonesia |
| Phone: | 6289653107340 |
| Organization Email: | headoffice@empatbintang.com |
| Web Site: | http://empatbintang.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 1602230090538 |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| We developed Afiya AI, our cutting-edge TB treatment failure classification model, stands at the forefront of healthcare innovation. Developed through meticulous research, our model has earned recognition by being published in a prestigious SCOPUS International Journal. Afiya AI harnesses advanced AI algorithms to analyze diverse data sets, enabling the early detection of TB treatment failures. By identifying at-risk patients sooner, healthcare providers can tailor treatment strategies more effectively, greatly enhancing patient outcomes. Beyond early detection, Afiya AI aims to revolutionize TB management by providing insights into treatment optimization, risk assessment, and patient monitoring. Our vision extends to leveraging AI in transforming the landscape of TB care, making health systems more proactive, predictive, and personalized. |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Delivery of health services and care Research and Development Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 11 - 25 |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 1 - 5 |
| How did you hear about the Stop TB Partnership: | Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Technical assistance and advice |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Both national and international bodies have prioritized TB elimination, with ambitious goals set for 2035. The urgency for innovative solutions and comprehensive strategies to combat TB has never been greater. The escalating TB crisis demands immediate attention and action. Afiya AI emerges as a revolutionary tool in the global fight against Tuberculosis, offering hope through advanced AI-driven analytics and intervention strategies. Afiya AI plans to secure exclusive licensing rights for our TB treatment failure classification model, ensuring it becomes a proprietary asset that can be continuously enhanced and adapted to meet evolving healthcare needs. |
|
Geographical Reach | |
| Which country is your headquarters located in: | Indonesia |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Indonesia |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: With a focus on developing countries where TB prevalence is high, Afiya AI’s business model is not just about profitability; it's about creating sustainable, long-term impact by making advanced healthcare analytics accessible to all segments of the healthcare industry, from frontline hospitals to research institutions. Research: By collaborating with health ministries, international health organizations, and educational institutions, Afiya AI aims to be at the forefront of the global fight against TB, driving innovation and excellence in healthcare solutions. |
|
Declaration | |
| Declaration of interests: As part of our commitment to transparency and ethical conduct, Afiya AI declares that there are no financial or other interests that could constitute a real, potential, or apparent conflict of interest with respect to our involvement in the Global Partnership to Stop TB. Our primary mission is to leverage artificial intelligence to improve TB treatment outcomes, which aligns with the objectives of the Stop TB Partnership. Our funding sources, research activities, and business operations are conducted with the utmost integrity, aimed solely at contributing positively to the fight against TB. We have no financial ties or interests in pharmaceutical companies or other entities that could unduly influence our work or the objectivity and independence of the Stop TB Partnership. We understand the importance of maintaining the credibility and effectiveness of the Global Partnership to Stop TB and are committed to ensuring that our involvement strengthens rather than compromises these efforts. Should any potential conflict of interest arise in the future, we pledge to report it promptly to the Executive Secretary of the Stop TB Partnership for review and assessment. We appreciate the opportunity to be part of this vital global health initiative and are dedicated to contributing our expertise and solutions to help achieve its goals. | |
| Application date: | March 8, 2024 |
| Last updated: | March 8, 2024 |